Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
Bea Campforts, Marjan Drukker, Therese van Amelsvoort, Maarten Bak · 2024
Read Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study by Bea Campforts, Marjan Drukker, Therese van Amelsvoort, Maarten Bak (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11607825.txt.
Description
Bea Campforts and three co-authors ran a pilot study on weight drugs for psychiatric patients in a 2024 paper. Antipsychotic medicines often cause heavy weight gain, which adds health risks to mental illness. A diabetes drug class that curbs appetite has drawn interest as a counter. The pilot compared one such drug, semaglutide, with the older standard, metformin.
Patients in routine outpatient care took the drugs by mouth for sixteen weeks. Ten on semaglutide lost about four and a half kilos on average, about four percent of body weight. Twenty-six on metformin lost about two and a half percent. Waist size and body mass index fell in both groups. The study was small and not randomized, so it cannot settle which drug is better. The authors present it as a first real-world check that the newer drug works in this hard-hit group.
Catalog record
| CREATOR | Bea Campforts, Marjan Drukker, Therese van Amelsvoort, Maarten Bak |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |